Collumbotai Bio-B (06990) is now up more than 4%. As of press release, it has risen 4.08% to HK$137.9, with a turnover of HK$10.811 million.
The Zhitong Finance App learned that Columbite Biotech (06990) is now up more than 4%. As of press release, it has risen 4.08% to HK$137.9, with a turnover of HK$10.811 million.
Guolian Securities pointed out that at the 2024 AACR conference, the SKB-264 lung cancer data presented by Columbotai was impressive, showing the potential for treating a wide range of tumors. Colombotech SKB264 is currently undergoing phase II and phase III clinical trials of single drugs/combinations for multiple cancer types around the world, and is expected to become a major ADC product with significant benefits for pan-cancer types.
The bank pointed out that overseas, MSD has launched seven global phase III clinical trials, which cover almost the vast majority of NSCLC patients with lung cancer indications from early stage to terminal. In addition, it also targets gastric cancer, endometrial cancer, and HR+/HER2 (low/-) breast cancer endpoints; domestically, Colombotai's cancer layout has advanced clinical progress and has been recognized by regulators.